Skip to main content
SpringerLink
Log in

Mirvetuximab Soravtansine: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere™) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. The ADC is being developed by ImmunoGen for the treatment of FRα expressing cancers. In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1–3 prior systemic treatment regimens. This article summarizes the milestones in the development of mirvetuximab soravtansine leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in Ovarian cancer models. Neoplasia. 2016;18(12):775–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FR alpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR alpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Food & Drug Administration. FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer [media release]. 14 Nov 2022. https://www.fda.gov/

  4. ImmunoGen. ElahereTM (mirvetuximab soravtansine-gynx) injection, for intravenous use. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf. Accessed 28 Nov 2022.

  5. Yam C, Rauch GM, Rahman T, et al. A phase II study of mirvetuximab soravtansine in triple-negative breast cancer. Invest New Drugs. 2021;39(2):509–15.

    Article  CAS  PubMed  Google Scholar 

  6. National Comprehensive Cancer Network. NCCN receives $2-million funding commitment from ImmunoGen Inc. to study mirvetuximab soravtansine for folate receptor alpha-positive cancers [media release]. 18 May 2015. http://www.nccn.org.

  7. National Comprehensive Cancer Network. NCCN awards research grants to eight investigators to support clinical and pre-clinical studies of mirvetuximab soravtansine in various cancers [media release]. 7 Jun 2016. http://www.nccn.org.

  8. ImmunoGen, Merck. ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with Keytruda®(pembrolizumab) for the treatment of ovarian cancer [media release]. 4 Feb 2016. http://www.immunogen.com.

  9. ImmunoGen, Huadong Medicine. ImmunoGen and Huadong Medicine announce strategic collaboration to develop and commercialize mirvetuximab soravtansine in Greater China [media release]. 20 Oct 2020. www.immunogen.com.

  10. Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015;14(7):1605–13.

    Article  CAS  PubMed  Google Scholar 

  11. Altwerger G, Bonazzoli E, Bellone S, et al. In vitro and In vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018;17(5):1003–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chelariu-Raicu A, Stur E, Ivan C, et al. Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer [abstract no 1237]. Cancer Res. 2020;80(16 Suppl):2.

    Google Scholar 

  13. Moore KN, Lorusso D, Oaknin A, et al. Population pharmacokinetic analysis of mirvetuximab soravtansine in patients with folate receptor α–positive cancer [abstract no 605P]. Ann Oncol. 2022;33(Suppl 7):S822–3.

    Article  Google Scholar 

  14. Matulonis U, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study [abstract no LBA4]. Gynecol Oncol. 2022;166(Suppl 1):S50.

    Article  Google Scholar 

  15. Matulonis UA, Oaknin A, Pignata S, et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: characterization of antitumor activity in the SORAYA study [abstract no 5512]. J Clin Oncol. 2022;40(16 Suppl):1.

    Google Scholar 

  16. Coleman RL, Lorusso D, Oaknin A, et al. Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the SORAYA study [abstract no. 376]. Int J Gynecol Cancer. 2022;32(Suppl 3).

  17. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757–65.

    Article  CAS  PubMed  Google Scholar 

  18. Moore KN, Oza AM, Colombo N, et al. Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) [abstract no 532P]. Ann Oncol. 2022;33(Suppl 7):S790–1.

    Article  Google Scholar 

  19. Moore K, Oza A, Colombo N, et al. FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) [abstract no 992O]. Ann Oncol 2019;30 (Suppl 5):v403.

  20. Oaknin A, Lorusso D, Oza A, et al. Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alphapositive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine [abstract no. 2022-RA-660-ESGO and poster presentation]. Int J Gynecol Cancer. 2022;32(Suppl 2):A2251–2.

    Google Scholar 

  21. Matulonis UA, Moore KN, Lorusso D, et al. Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor [alpha] (FR[alpha])-positive cancer [abstract no 592P]. Ann Oncol. 2022;33(Suppl 7):S817.

    Article  Google Scholar 

  22. O’Malley DM, Oaknin A, Matulonis UA, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis [abstract no 5504]. J Clin Oncol. 2021;39(15 Suppl):3.

    Google Scholar 

  23. O’Malley DM, Richardson DL, Vergote IB, et al. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer [abstract no. 833P]. Ann Oncol. 2020;31(Suppl 4):S626–7.

    Article  Google Scholar 

  24. O’Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379–85.

    Article  CAS  PubMed  Google Scholar 

  25. ImmunoGen. ImmunoGen announces positive findings from the FORWARD II study of mirvetuximab soravtansine combination regimens with Avastin® and carboplatin in ovarian cancer [media release]. 16 May 2018. http://www.immunogen.com.

  26. Moore, KN, O'Malley DM, Vergote I, et al. Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis [abstract no 499]. Int J Gynecol Cancer. 2022;32(Suppl 3):A33–4.

  27. Matulonis U, Moore K, Martin L, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): initial results of an expansion cohort from FORWARD II, a phase Ib study [abstract no 949P]. Ann Oncol. 2018;29(Suppl 8):viii339.

    Article  Google Scholar 

  28. O’Malley D, Oaknin A, Matulonis U, et al. Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab [abstract no 496]. Int J Gynecol Cancer. 2022;32(Suppl 3):16–7.

    Google Scholar 

  29. Backes F, Wei L, Copeland L, et al. Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer [abstract no 120]. Gynecol Oncol. 2021;162(Suppl 1):S68–9.

    Article  Google Scholar 

  30. Cristea MC, Ruel NH, Frankel PH, et al. A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (pts) with selected FR alpha-positive solid tumors: results in the ovarian cancer (EC) cohort [abstract no. 5542]. J Clin Oncol. 2021;39(15 Suppl).

  31. Moore KN, Borghaei H, O’Malley DM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080–7.

    Article  CAS  PubMed  Google Scholar 

  32. Moore KN, Martin LP, O’Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112–8.

    Article  CAS  PubMed  Google Scholar 

  33. ImmunoGen. ImmunoGen announces new clinical data with mirvetuximab soravtansine in ovarian cancer to be presented at 2017 ASCO annual meeting [media release]. 18 May 2017. http://www.immunogen.com.

  34. Moore KN, Lorusso D, Oaknin A, et al. Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: phase 1 and 3 clinical trials [abstract no 5574]. J Clin Oncol. 2022;40(16 Suppl):1.

    Google Scholar 

  35. Roche. Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for Elahere [media release]. 14 Nov 2022. http://www.roche.com.

  36. Roche. VENTANA FOLR1 (FOLR1-2.1) RxDx Assay label. 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220006C.pdf. Accessed 30 Dec 2022.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Young-A Heo

Authors
  1. Young-A Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-A Heo.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethical Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 216 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heo, YA. Mirvetuximab Soravtansine: First Approval. Drugs 83, 265–273 (2023). https://doi.org/10.1007/s40265-023-01834-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01834-3

Search

Navigation